Engineered stem cells could evade immune system rejection, study shows
By editing out a set of proteins on the surface of human pluripotent stem cells, researchers have ensured they will be not be rejected by the body's immune system.
List view / Grid view
By editing out a set of proteins on the surface of human pluripotent stem cells, researchers have ensured they will be not be rejected by the body's immune system.
In human cells, a drug candidate called PF-00835231 has demonstrated success at blocking the reproduction of SARS-CoV-2.
The component, now developed into a drug called Ab8, was highly effective at treating and preventing SARS-CoV-2 infection in animal models.
The detailed analysis of adenosquamous cancer of the pancreas (ASCP) suggested FGFR and RORC were two promising therapeutic targets.
Researchers have developed a molecule that can restore lost connections in the spinal cords and brains of mice with cerebellar ataxia, Alzheimer's disease and spinal cord injury.
By targeting a previously undiscovered allosteric site on a DMD-associated enzyme, researchers found muscle cell conditions improved.
Scientists have found two active substances that allowed cells to reactivate the production of a protein that prevents the onset of Parkinson's disease.
A new tool called COVID-3D that monitors SARS-CoV-2 genome mutations could aid drug and vaccine development, its creators say.
Researchers have revealed that the antibiotic concanamycin A targets a protein called Nef, allowing the immune system to destroy HIV in cells.
Using scanning electron microscopy, researchers have captured images of epithelial cell cultures infected by SARS-CoV-2.
Following their success in organoid systems, two drug candidates are now to be administered to ferrets and tested against COVID-19.
Researchers have captured the assembly of orthoreovirus, part of the Reoviridae family, inside infected cells using cryo-electron tomography.
Human genome-produced RNA has been found on the surface of human cells, which researchers say could be easier for therapeutics to reach.
The study evaluating Down syndrome endothelial cells presented novel drug targets for leukaemia and suggested why DS patients may be at greater risk from the cancer.
Researchers suggest possible therapies for macrophage activation syndrome (MAS), a feature of cytokine storm and a major cause of death in severe COVID-19 patients.